Therapy Areas: Devices
Imvaria Shows Data Demonstrating Non-Invasive Digital Biomarker for Predicting Mortality in Interstitial Lung Diseases
23 May 2023 - - US-based health tech company Imvaria Inc., developing AI-driven digital biomarker solutions, has posted data from a study evaluating the company's lead non-invasive digital biomarker Fibresolve showing the tool's supplemental ability to predict mortality in patients with interstitial lung disease, the company said.

The results will be presented on May 24 as an oral presentation at the Mini Symposium "Looking for the Crystal Ball: Biomarkers to Predict Disease Progression and Mortality in ILD" at the American Thoracic Society 2023 International Conference (ATS 2023) in Washington, DC.

Interstitial lung diseases are a group of lung diseases characterized by progressive scarring of lung tissue that causes progressive difficulty in breathing and early death, particularly if untreated.

Standard diagnosis is done with CT scan along with lung function testing, which is evaluated through measuring lung volumes. However, risky, invasive and costly procedures, such as lung biopsy, can be required for specific diagnosis and prognostication.

Therefore, a low-cost, widely-accessible software tool to help clinicians diagnose, risk assess, and subsequently treat patients could potentially be the difference between improved prognosis or significant disability.

Imvaria's Fibresolve is being developed to serve as adjunct in assessment of ILD, including idiopathic pulmonary fibrosis, potentially avoiding expensive, invasive surgical testing. Fibresolve uses AI to analyze CT imaging for specific, novel patterns.

The software has Breakthrough Devices Designation from the Food and Drug Administration and is currently for investigational-use only.

In the study presented at ATS 2023 titled "Chest Computed Tomography Machine Learning Classifier for Idiopathic Pulmonary Fibrosis Predicts Mortality in Interstitial Lung Diseases," researchers from Imvaria and its collaborators assessed Fibresolve in 228 patients with IPF and other ILD, adjusting for Gender, Age, and Physiology score (including forced vital capacity or FVC).

In all models tested, Fibresolve significantly predicted the risk of death in ILD patients.

The company also announced three additional poster presentations at ATS 2023 demonstrating the development and utility of Fibresolve.